Analyst Price Target is $8.90
▲ +14,514.12% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Kaleido Biosciences in the last 3 months. The average price target is $8.90, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 14,514.12% upside from the last price of $0.06.
Current Consensus is
The current consensus among 3 polled investment analysts is to hold stock in Kaleido Biosciences. This rating has held steady since December 2020, when it changed from a Sell consensus rating.
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.